explore -WSS

explore

author：knowledge 2025-09-27 23:33:00 - browse：74

Chris O'Meara/AP

Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Brain injuries and the importance of a second opinion

WSS

Why Eli Lilly’s earnings didn’t quite live up to the hype

Ebola vaccine can save some who are already sick, per new study

Prime Medicine says its gene editing passes test in monkeys

Key Senate panel to consider PBM, drug pricing reform package

Resistance to opioid

Congress must protect the remaining independent doctors

explore

explore

leisure time

How one medical school became remarkably diverse

Latigo launches with $135 million for Vertex

Virginia high school admissions case could be legal follow

Having children helps parents live longer, especially after age 80

How one medical school became remarkably diverse

Websites selling Wegovy, Zepbound ingredients targeted by FDA

The cancer drug shortage isn’t new — and neither are the solutions

Coloradans with cystic fibrosis could lose access to Trikafta

Medicare proposal to cover medical devices draws a mixed reaction

Long Covid research funding gets a major boost from NIH

entertainment

Congress considering partial increase for doctor pay in Medicare

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Why Eli Lilly’s earnings didn’t quite live up to the hype

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

All of Us, NIH's precision medicine initiative, gets a big boost

leisure time

focus

hotspot

hotspot